First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes ANB033, a novel anti-CD122 antagonist targeting the shared beta subunit of the IL-15 and IL-2 receptors. The company also has Rosnilimab, an antibody designed to selectively deplete pathogenic T cells in both the periphery and inflamed tissues, and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells (pDCs). These products aim to address unmet medical needs in autoimmune and inflammatory conditions.

First Tracks Biotherapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TRAX. The company's financials are reported in US Dollars (USD), reflecting its headquarters and primary operations in the United States.

First Tracks Biotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology firm, it focuses on researching and developing novel immunology-based therapies for autoimmune and inflammatory diseases, distinguishing it from broader healthcare companies.

First Tracks Biotherapeutics is headquartered in San Diego, California, United States. The company primarily serves the United States market, as indicated by its focus on delivering immunology therapeutics within the country. Its operations are based in the US, and it was founded in 2019.

First Tracks Biotherapeutics, Inc. was originally known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. The company was founded in 2019 and is based in San Diego, California. This rebranding reflects its strategic focus on developing immunology therapeutics for autoimmune and inflammatory diseases.